PLT granted expanded license for Slendacor weight loss ingredient


Health Canada has approved weight management claims previously for the product

PLT granted expanded license for Slendacor weight loss ingredient

PLT Health Solutions has received an expanded license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its Slendacor weight management complex to support healthy weight loss in Canada. The product’s approach to weight management works by inhibiting the accumulation of fat in fat cells (lipogenesis) and enhancing the body’s ability to break down fat (lipolysis). The ingredient has been clinically shown to enhance weight loss.

In Canada, previously approved claims include that it exerts complementary weight management benefits when combined with a reduced-calorie diet and regular physical activity and is clinically shown to assist in weight management when used with a program of reduced-calorie intake and regular physical activity.

The NPN adds claims for Slendacor that include support of healthy cholesterol and triglycerides, asserting the product helps lower blood triglycerides, total and LDL cholesterol and also helps support cardiovascular health by reducing total and LDL cholesterol. The NNHPD also allows for claims the product could be a complement to a healthy lifestyle that incorporates a calorie-educed diet and regular physical activity for individuals involved in a weight management/maintenance program.

Jeremy Appleton, ND, Director of Medical & Scientific Affairs at PLT Health Solutions, said: “Healthy weight management has never been solely about shedding pounds. As important as weight loss is to many consumers, they know that healthy and sustainable changes to body weight must involve supporting other related systems, like cardiovascular and metabolic health. These new approved claims mean that we all can better understand Slendacor as an integral part of a holistic health management program, one that includes body weight, but in the greater context of cardiometabolic health,” he said.

Sign up for your free email newsletter

Slendacor has been shown effective in double-blind clinical trials in both obese and healthy overweight subjects, with statistically significant improvements beginning in two weeks and continuing through the end of the studies.

Featured Companies